Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Colorectal Neoplasms 35Pancreatic Neoplasms 19Colonic Neoplasms 10Rectal Neoplasms 8Stomach Neoplasms 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Neoplasms 6Neoplasm Metastasis 6Gastrointestinal Neoplasms 6Esophageal Neoplasms 6Carcinoma, Non-Small-Cell Lung 5Biliary Tract Neoplasms 5Advanced Solid Tumors 4Triple Negative Breast Neoplasms 3Melanoma 3Endometrial Neoplasms 3Carcinoma, Squamous Cell 3Adenocarcinoma Of Esophagus 3Squamous Cell Carcinoma of Head and Neck 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Liver Neoplasms 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Hepatocellular 2Carcinoma 2Subjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0; Stages II and III) and Histologically-Confirmed Intestinal GC 1Solid Cancer 1Small Cell Lung Carcinoma 1Sarcoma 1

Interventions

pembrolizumab 9avelumab 8Nivolumab 6Ipilimumab 4Radiotherapy 3durvalumab 2cemiplimab 2atezolizumab 2aldesleukin 2Specimen Handling 2Radiation 2Magnetic Resonance Spectroscopy 2Interferon-beta 2Cyclophosphamide 2Biopsy 2Bevacizumab 2tremelimumab 1sargramostim 1sapanisertib 1regorafenib 1prednylidene 1poly ICLC 1navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1lutetium Lu 177 dotatate 1interferon gamma-1b 1epacadostat 1efineptakin alfa 1deltacortene 1decitabine and cedazuridine drug combination 1bempegaldesleukin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Merkel Cell × Leucovorin × Clear all
NCT03167164 2025-02-21

QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy

ImmunityBio, Inc.

Phase 1/2 Withdrawn
Dermatologic

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡